Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Shares Outstanding (Diluted Average) (2022 - 2025)

Atara Biotherapeutics' Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $12.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 69.85% year-over-year to $12.7 million; the TTM value through Dec 2025 reached $12.7 million, up 69.85%, while the annual FY2025 figure was $12.7 million, 69.85% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $12.7 million in Q4 2025 per ATRA's latest filing, up from $12.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $104.0 million in Q1 2023 to a low of $4.2 million in Q2 2023.
  • Average Shares Outstanding (Diluted Average) over 4 years is $37.2 million, with a median of $11.2 million recorded in 2025.
  • Peak YoY movement for Shares Outstanding (Diluted Average): tumbled 95.87% in 2023, then soared 92.98% in 2025.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $102.0 million in 2022, then plummeted by 95.85% to $4.2 million in 2023, then surged by 76.77% to $7.5 million in 2024, then soared by 69.85% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Shares Outstanding (Diluted Average) are $12.7 million (Q4 2025), $12.3 million (Q3 2025), and $11.6 million (Q2 2025).